Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-12.16%
operating margin TTM
-27.37%
revenue TTM
2.45 Million
revenue per share TTM
0.05$
valuation ratios | |
|---|---|
| pe ratio | -13.95 |
| peg ratio | -0.45 |
| price to book ratio | 0.56 |
| price to sales ratio | 1.70 |
| enterprise value multiple | -12.11 |
| price fair value | 0.56 |
profitability ratios | |
|---|---|
| gross profit margin | 77.83% |
| operating profit margin | -27.37% |
| pretax profit margin | -12.16% |
| net profit margin | -12.16% |
| return on assets | -3.73% |
| return on equity | -3.94% |
| return on capital employed | -8.77% |
liquidity ratio | |
|---|---|
| current ratio | 22.63 |
| quick ratio | 22.63 |
| cash ratio | 5.27 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 15.25 |
| days of payables outstanding | 23.95 |
| cash conversion cycle | -8.70 |
| receivables turnover | 23.94 |
| payables turnover | 15.24 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | 0.04 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -0.26 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.05 |
| cash per share | 4.47 |
| operating cash flow per share | -0.04 |
| free cash flow operating cash flow ratio | 1.13 |
| cash flow coverage ratios | -0.26 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -7.98 |
Frequently Asked Questions
When was the last time Fulcrum Therapeutics, Inc. (NASDAQ:FULC) reported earnings?
Fulcrum Therapeutics, Inc. (FULC) published its most recent earnings results on 13-11-2024.
What is Fulcrum Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Fulcrum Therapeutics, Inc. (NASDAQ:FULC)'s trailing twelve months ROE is -3.94%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Fulcrum Therapeutics, Inc. (FULC) currently has a ROA of -3.73%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did FULC's net profit margin stand at?
FULC reported a profit margin of -12.16% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is FULC's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 22.63 in the most recent quarter. The quick ratio stood at 22.63, with a Debt/Eq ratio of 0.04.